NDAORALTABLET
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZURAMPIC (lesinurad) is an oral urate transporter inhibitor approved in 2015 for the treatment of hyperuricemia in patients with gout. It works by inhibiting renal urate reabsorption, thereby increasing urinary uric acid excretion. The drug is typically used as an adjunct to xanthine oxidase inhibitors in patients who do not achieve target serum uric acid levels with monotherapy.
Peak5.4 years to LOE
Product is in peak commercial phase with established market presence; team size and staffing likely stable with emphasis on optimization and retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Post-Authorisation Safety Study of Lesinurad
Started Jan 2021
0GoutHyperuricemia
A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment
Started Jul 2017
242 enrolled
GoutChronic Kidney Disease (CKD)
Career Relevance
ZURAMPIC offers career opportunities in established brand management and commercial execution within the specialty pharma space, though limited clinical expansion means fewer medical development roles. Professionals should expect stable, optimization-focused work with growing emphasis on lifecycle extension and LOE preparation.
Brand Manager
Worked on ZURAMPIC at Ironwood Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.